TY - JOUR
T1 - Screening for drug related dyspepsia
T2 - An analysis of prescription symmetry
AU - Hallas, Jesper
AU - Bytzer, Peter
PY - 1998/1/1
Y1 - 1998/1/1
N2 - Objective. Most patients with severe upper dyspepsia are treated empirically with ulcer drugs. Drug-induced dyspepsia might therefore be reflected in the sequencing of ulcer drugs relative to other medications. Our aim was to screen a large population-base prescription database for evidence of drug-induced dyspepsia. Methods. Prescription data on 31,232 incident users of ulcer drugs were drawn from a research database, covering the county of Funen, Denmark. We identified all individuals who had started their first recorded therapies with an ulcer drug and another non-ulcer drug within a 100 day span. In this selected group, there would normally be an equal number starting either drug first, while a dyspepsia-provoking effect of the non-ulcer drug would manifest as an excess of individuals with the ulcer drug prescribed last. This screening method is robust to confounders that are stable over time. Results. Only non-steroidal antiinflammatory drugs (adjusted rate ratio (RR) 1.8, 95% confidence interval (CI), 1.6-2.0), calcium blockers (RR 1.4, CI 1.2-1.7), corticosteroids (RR 1.1, CI 1.0-1.3), angiotensin converting enzyme inhibitors (RR 1.4, CI 1.1-1.7) and methylxanthines (RR 1.5, CI 1.1-2.2) showed a significant asymmetry suggesting a dyspepsia-provoking effect. An analysis of effect modifiers suggested that the signals for corticosteroids and for angiotensin converting enzyme inhibitors were explained by concurrent use of nonsteroidal anti-inflammatory drugs and by underlying congestive heart failure. The signal for non-steroidal antiinflammatory drugs may be explained by the known reputation of non-steroidal antiinflammatory drugs for causing ulcers. Conclusion. There are hardly any important unknown drug effects that mimic acid related dyspepsia. Drug-induced dyspepsia contributes little to the overall use of ulcer drugs.
AB - Objective. Most patients with severe upper dyspepsia are treated empirically with ulcer drugs. Drug-induced dyspepsia might therefore be reflected in the sequencing of ulcer drugs relative to other medications. Our aim was to screen a large population-base prescription database for evidence of drug-induced dyspepsia. Methods. Prescription data on 31,232 incident users of ulcer drugs were drawn from a research database, covering the county of Funen, Denmark. We identified all individuals who had started their first recorded therapies with an ulcer drug and another non-ulcer drug within a 100 day span. In this selected group, there would normally be an equal number starting either drug first, while a dyspepsia-provoking effect of the non-ulcer drug would manifest as an excess of individuals with the ulcer drug prescribed last. This screening method is robust to confounders that are stable over time. Results. Only non-steroidal antiinflammatory drugs (adjusted rate ratio (RR) 1.8, 95% confidence interval (CI), 1.6-2.0), calcium blockers (RR 1.4, CI 1.2-1.7), corticosteroids (RR 1.1, CI 1.0-1.3), angiotensin converting enzyme inhibitors (RR 1.4, CI 1.1-1.7) and methylxanthines (RR 1.5, CI 1.1-2.2) showed a significant asymmetry suggesting a dyspepsia-provoking effect. An analysis of effect modifiers suggested that the signals for corticosteroids and for angiotensin converting enzyme inhibitors were explained by concurrent use of nonsteroidal anti-inflammatory drugs and by underlying congestive heart failure. The signal for non-steroidal antiinflammatory drugs may be explained by the known reputation of non-steroidal antiinflammatory drugs for causing ulcers. Conclusion. There are hardly any important unknown drug effects that mimic acid related dyspepsia. Drug-induced dyspepsia contributes little to the overall use of ulcer drugs.
KW - ACE-inhibitors
KW - Adverse drug effect
KW - Calcium channel blockers
KW - Corticosteroids
KW - Dyspepsia
KW - NSAID
KW - Theophylline
KW - Ulcer drugs
UR - http://www.scopus.com/inward/record.url?scp=0031932595&partnerID=8YFLogxK
U2 - 10.1097/00042737-199801000-00006
DO - 10.1097/00042737-199801000-00006
M3 - Article
C2 - 9512950
AN - SCOPUS:0031932595
SN - 0954-691X
VL - 10
SP - 27
EP - 32
JO - European Journal of Gastroenterology and Hepatology
JF - European Journal of Gastroenterology and Hepatology
IS - 1
ER -